Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. While ABT may outperform JNJ over the next three years, it is helpful to see how Abbott’s Peers fare on metrics that matter. With higher inflation and the Fed raising interest rates, among other factors, ABT stock has fallen 12% in the last twelve months.